gms | German Medical Science

Gesundheit – gemeinsam. Kooperationstagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie (GMDS), Deutschen Gesellschaft für Sozialmedizin und Prävention (DGSMP), Deutschen Gesellschaft für Epidemiologie (DGEpi), Deutschen Gesellschaft für Medizinische Soziologie (DGMS) und der Deutschen Gesellschaft für Public Health (DGPH)

08.09. - 13.09.2024, Dresden

Preferences on treatment decision making in sarcoma patients. Prevalence and associated factors – results from the PROSa Study

Meeting Abstract

  • Martin Eichler - NCT/ UCC Dresden, Dresden, Germany
  • Hanna Salm - University Hospital Greifswald, Greifswald, Germany; Helios Hospital Bad Saarow, Bad Saarow, Germany
  • Leopold Hentschel - University Hospital Carl Gustav Carus, Dresden, Germany
  • Jochen Schmitt - TU Dresden, Dresden, Germany
  • Markus K. Schuler - University Hospital Carl Gustav Carus Dresden, Dresden, Germany

Gesundheit – gemeinsam. Kooperationstagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie (GMDS), Deutschen Gesellschaft für Sozialmedizin und Prävention (DGSMP), Deutschen Gesellschaft für Epidemiologie (DGEpi), Deutschen Gesellschaft für Medizinische Soziologie (DGMS) und der Deutschen Gesellschaft für Public Health (DGPH). Dresden, 08.-13.09.2024. Düsseldorf: German Medical Science GMS Publishing House; 2024. DocAbstr. 760

doi: 10.3205/24gmds823, urn:nbn:de:0183-24gmds8239

Veröffentlicht: 6. September 2024

© 2024 Eichler et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.


Gliederung

Text

Introduction: The impact of being diagnosed with a life-threatening illness may influence preferences to participate in treatment decisions. The objective of this analysis was to identify factors that are associated with sarcoma patients wanting to take a more active or passive role.

Methods: Data was obtained as part of a nationwide multicenter trial (PROSa) aiming to investigate the structure and quality of medical care of sarcoma patients in Germany and their determinants. The study was conducted between 2017 and 2020 in 39 study centers.

For the present analysis, cross-sectional data of adult patients with sarcoma of any entity were analyzed. Control preference was measured with the control preference scale (CPS). Preferences were divided in patient-led, shared, or physician-led-decision-making.

Associated factors were analyzed exploratively using multivariable multinomial logistic regression models. We included socio-economical and medical variables with stepwise backward variable selection.

Results: We included 1081 patients (48.6% female). 402 patients (37.2%) preferred to be in control about treatment decisions, while 400 patients (37.0%) favored shared responsibility.

25.8% (n = 279) wished to rather leave the control to the treating physician.

When comparing the patients who preferred physician-led decision making with those who favored shared responsibility, older patients were more likely to prefer shared decision-making compared to those 18 to > 40 years old (age group: > 75 years: Odds Ratio (OR) .53, 95% confidence interval (95% CI) .28; .99). Patients with a metastatic tumor desired shared decision making compared to those without metastases (metastasis: OR 1.61, 95% CI 1.09; 2.38).

When comparing the patients who preferred physician-led decision making with those who favored to be in control, older patients also preferred leaving the control to the physician and were less inclined to make the decisions by themselves: (18 to > 40 years vs > 75 years: OR .28, 95% CI .15; .55). With secondary school (8/9 years) as reference, patients holding a high school degree were more likely to prefer patient-led decision-making over physician-led decision making (OR 2.00, 95% CI 1.26; 3.09). Patients with sarcoma of the abdomen/retroperitoneum were more predisposed to taking control in treatment decisions compared to those with sarcoma of the back/spine or lower limb (back/spine: OR .18, 95% CI .06; .54, lower limb: OR .56, 95% CI .37; .85). With an income of 1250 €/month as reference, patients with a higher income were more likely to take control (> 2750€/month: OR 1.7, 95% CI 1.0; 3.1).

Conclusion: The findings of our study demonstrate that patients with metastatic disease are more likely to seek a joint decision, while those of higher age and lower education level are less likely to actively participate in treatment decisions. The results suggest that the impact of advanced illness may influence preferences to participate. Additionally, our findings indicate differences in participation preferences based on the tumor’s location, a finding that should be further investigated.

The authors declare that they have no competing interests.

The authors declare that a positive ethics committee vote has been obtained.